8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 1, 2019)

Filed May 1, 2019For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 1, 2019, primarily to announce its financial results for the quarter ended March 31, 2019. The core of this filing is the accompanying press release (Exhibit 99.1) which provides the detailed financial performance and operational updates for the period. Investors should note that the information furnished under Item 2.02, including the press release, is not considered "filed" under the Securities Exchange Act of 1934. This means it's not subject to the liabilities of Section 18 and is not automatically incorporated into other SEC filings. For a comprehensive understanding of the quarter's performance, investors must refer directly to the content of the furnished press release.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its Q1 2019 financial results on May 1, 2019.
  • 2The key details of the financial performance are contained within an attached press release (Exhibit 99.1).
  • 3The filing is an 8-K Current Report.
  • 4The report includes information on the company's Results of Operations and Financial Condition (Item 2.02).
  • 5Financial Statements and Exhibits are also listed, with the press release being the primary exhibit.
  • 6The Chief Financial Officer, Manmeet S. Soni, signed the filing.
  • 7Information furnished under Item 2.02 is not deemed 'filed' for certain legal purposes.

Frequently Asked Questions

The main purpose of this 8-K filing from Alnylam Pharmaceuticals on May 1, 2019, is to announce the company's financial results for the first quarter ended March 31, 2019. The detailed information is provided in an accompanying press release.

The actual financial results and operational updates for the quarter ended March 31, 2019, are located in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should review this press release for specific figures and commentary.

The information furnished under Item 2.02 of this 8-K, including the press release, is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same legal liabilities as a formally filed document and is not automatically incorporated into other SEC filings unless specifically referenced.

The 8-K filing was signed by Manmeet S. Soni, who is the Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc.